Home Table of Contents

§ 21-2A-06.1. Confidentiality and disclosure of naloxone medication data

West's Annotated Code of MarylandHealth--GeneralEffective: October 1, 2022

West's Annotated Code of Maryland
Health--General
Title 21. Food, Drugs, and Cosmetics (Refs & Annos)
Subtitle 2a. Prescription Drug Monitoring Program (Refs & Annos)
Effective: October 1, 2022
MD Code, Health - General, § 21-2A-06.1
§ 21-2A-06.1. Confidentiality and disclosure of naloxone medication data
Currentness
Confidentiality
(a) Naloxone medication data:
(1) Are confidential and privileged, and not subject to discovery, subpoena, or other means of legal compulsion in civil litigation;
(2) Are not public records; and
(3) Except as provided in subsection (b) of this section or as otherwise by law, may not be disclosed to any person.
Disclosure
(b)(1) The Program shall disclose naloxone medication data, in accordance with regulations adopted by the Secretary, for public health surveillance, research, analysis, public reporting, and education after redaction of all information that could identify a patient, prescriber, dispenser, or any other individual.
(2) The Secretary may require submission of an abstract explaining the scope and purpose of the research, analysis, public reporting, or education before disclosing naloxone medication data under paragraph (1) of this subsection.

Credits

Added by Acts 2022, c. 224, § 1, eff. Oct. 1, 2022.
MD Code, Health - General, § 21-2A-06.1, MD HEALTH GEN § 21-2A-06.1
Current through legislation effective through April 9, 2023, from the 2024 Regular Session of the General Assembly. Some statute sections may be more current, see credits for details.
End of Document